Scientists at the National Cancer Institute (NCI) developed a novel stealth lipid-based nanoparticle formulation comprising phospholipid, DC8,9PC and a polyethylene glycol-ated (PEGylated) lipid – such as DSPE-PEG2000 – that efficiently package a high amounts of hydrophobic photodynamic drug (PDT) – such as HPPH – in stable vesicles. This HPPH-loaded liposome system demonstrates higher serum stability and ambient temperature stability upon storage. It exhibits increased tumor accumulation and improved animal survival in mice tumor models compared to the formulation in current clinical trials. The NCI seeks co-development partners and/or corporate licensees for the application of the technology as an anti-cancer therapeutic.
Researchers at the National Cancer Institute discovered small-molecule compounds whose activity against HIV-1 integrase mutants confer greater resistance than currently approved INSTIs. Preliminary DMPK and ADME studies have been completed by the NCI researchers. The National Cancer Institute seeks partners to commercialize this class of compounds through licensing or co-development.
The promise of RNA interference based therapeutics is made evident by the recent surge of biotechnological drug companies that pursue such therapies and their progression into human clinical trials. The present technology discloses novel RNA and RNA/DNA nanoparticles including multiple siRNAs, RNA aptamers, fluorescent dyes, and proteins. The National Cancer Institute sees parties interested licensing this technology or in collaborative research to co-develop RNAi-based nanoparticle therapeutics for cancer and HIV.
NCI seeks partners to commercialize Griffithsin and Griffithsin tandemers as therapeutics for HIV infections that are resistant to native GRFT, specifically, additional studies on stability, toxicity, immunogenicity, and large-scale production.
The present invention describes novel virus-like particles (VLPs) that are capable of binding to and replicating within a target mammalian cell, including human cells. The claimed VLPs are safer than viral delivery because they are incapable of re-infecting target cells. The National Cancer Institute's Protein Expression Laboratory seeks parties interested in licensing the novel delivery of RNA to mammalian cells using virus-like particles.
Scientists at the National Cancer Institute's Molecular Targets Laboratory have discovered that Cnidarins as a novel class of highly potent proteins capable of blocking the HIV virus from penetrating T-cells. The National Cancer Institute seeks parties interested in collaborative research to license or co-develop large-scale recombinant production of cnidarins.
RNA interference (RNAi) is a naturally occurring cellular post-transcriptional gene regulation process that utilizes small double-stranded RNAs to trigger and guide gene silencing. By introducing synthetic RNA duplexes called small-interfering RNAs (siRNAs), we can harness the RNAi machinery for therapeutic gene control and the treatment of various diseases. The National Cancer Institute seeks partners to license or co-develop RNA, RNA-DNA, and DNA-RNA hybrid nanoparticles consisting of a DNA or RNA core with attached RNA or DNA hybrid duplexes.
IFN-gamma and IL-10 are cytokine signaling molecules that play fundamental roles in inflammation, cancer growth and autoimmune diseases. Unfortunately, there are no specific inhibitors of IFN-gamma or IL-10 on the market to date. The National Cancer Institute seeks parties interested in licensing or collaborative research to co-develop selective IL-10 and IFN-gamma peptide inhibitors.
Researchers at the National Cancer Institute (NCI) developed cell free methods for efficiently producing high titer, papillomavirus virus-based gene transfer vectors. These vectors can potentially be used for vaccines and/or cancer therapeutic applications. NCI seeks licensing and/or co-development research collaborations for further development of these vectors.
Tuberculosis (TB) is an infectious disease that typically affects the lungs. Current therapies include a panel of antibiotics given over a range of 6-9 months. As a result of the expense of treatment, the extended timeframe needed for effective treatment, and the scarcity of medicines in some developing countries, patient compliance with TB treatment is very low and results in multi-drug resistant TB (MDR-TB). There remains a need for a faster, more effective treatment for TB. NCI researchers seek licensing and/or co-development of peptide inhibitors of STAT3 and IL-10 developed to treat bacterial infections such as tuberculosis. See aslo: NIH inventions E-164-2007 and E-167-2010
The National Cancer Institute (NCI) seeks licensing and/or co-development research collaborations for a polymeric drug delivery platform that targets scavenger receptor A1 (SR-A1), a receptor highly expressed in macrophages, monocytes, mast cells, dendritic cells (myeloid lineages), and endothelial cells. The platform delivers various immunomodulatory therapeutic cargo including small molecule drugs, therapeutic peptides, and vaccines, to the lymphatic system and myeloid/antigen presenting cell (APC) sub-populations.
Scientists at the National Cancer Institute's Molecular Targets Laboratory have modified the Cnidarin-derived griffithsin compound to have greater storage time and stability. Griffithsin compounds are a class of highly potent proteins capable of blocking the HIV virus from penetrating T cells. The National Cancer Institute seeks parties interested in collaborative research to license or co-develop large-scale recombinant production of the compound.
Novel fusion proteins with good stability and potency against HIV-1. These fusion proteins have good drug properties and potential as prophylactics or therapeutics against HIV-1 infection. Researchers at the NCI seek licensing for the development and commercialization of novel fusion proteins as therapeutics or prophylactics against HIV-1 infection.
The National Cancer Institute (NCI) Vaccine Branch, seeks research co-development or licenses for a novel method of improving HIV vaccine efficacy by activating Ras signaling. Upregulating the Ras pathway can improve an HIV patient’s immune response to anti-retroviral vaccines.
Investigators at the National Cancer Institute (NCI) have discovered an adjuvanted mucosal subunit vaccine to prevent SARS-CoV-2 transmission and infection. The mucosal vaccine is composed of a novel molecular adjuvant nanoparticle that induces robust humoral and cellular immunity, as well as trained innate immunity with enhanced protection against respiratory SARS-CoV-2 exposure. The technology is available for potential licensing or collaborative research to co-develop these therapeutic targets.
Researchers at the National Cancer Institute (NCI) RNA Biology Laboratory have developed nanoparticles that can deliver an agent (i.e., therapeutic or imaging) and release the agent upon targeted photoactivation allowing for controlled temporal and localized release of the agent.
Scientists at the National Cancer Institute (NCI) have developed a novel delivery platform in which the scaffold of an anionic hydrogel (AcVES3) can be attenuated to deliver therapeutic small molecules, peptides, proteins, nanoparticles, or whole cells. The NCI seeks collaborators and licensees for the development of this technology in various clinical and laboratory applications.
Researchers at the University of California, Irvine (UCI) and NCI seek licensing for a new family of far-red to near-infrared emission coumarin-based luciferins (CouLuc) with complementary mutant enzymes.
Scientists at the National Cancer Institute (NCI) have discovered a bacterial exonuclease VII (ExoVII) inhibitor that increases the potency of widely used quinolone antibiotics targeting prokaryotic type IIA topoisomerases. NCI seeks research co-development partners and/or licensees for the development of ExoVII inhibitors as new antibiotic adjuvants to boost the efficacy of quinolone antibiotics and/or restore the susceptibility of resistant bacteria.